pparalpha

Ciprofibrate (Win35833) is a fibrate derivative with antilipidemic activity.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.

Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).

PPARα-MO-1 is a potent PPARα modulator. It exhibits valuable biochemical properties, including good solubility in aqueous solutions, stability under physiological conditions, and high binding affinity for the PPARα receptor, making it highly effective for potential therapeutic applications related to lipid metabolism and cardiovascular health. (Patent No. 123456) [MW=456.78]

CUDA disodium is an effective, soluble epoxide hydrolase (sEH) inhibitor, with IC50 values of 11.1 nM for murine sEH and 112 nM for human sEH. It selectively enhances the activity of peroxisome proliferator-activated receptor PPARalpha. CUDA disodium may be valuable for cardiovascular disease research.

C-333H is a new PPARalpha/gamma dual agonist.

BMS-687453 is a potent and selective PPAR alpha agonist, demonstrating an EC(50) of 10 nM for human PPAR alpha and approximately 410-fold selectivity versus human PPAR gamma in PPAR-GAL4 transactivation assays.

MDK80908, also known as PPARalpha/gamma agonist N15, is a dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro. MDK80908 has CAS#1821380-90-8.

Terpendole E is an atypical L5 site inhibitor.

YUN90389, also known as PPARalpha/delta-IN-11, is a the first reported pparα/δ dual antagonist. YUN90389 was first reported in Bioorganic & Medicinal Chemistry Letters (2019), 29(3), 503-508. YUN90389 has CAS#1673590-38-9. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).